The Food and Drug Administration will hold a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting on Jan. 22 to review modified risk tobacco product (MRTP) applications submitted by Swedish Match USA for 20 Zyn nicotine pouch products.
The flavors under review—each offered in 3 milligrams and 6 milligrams strengths—include:
- Chill
- Cinnamon
- Citrus
- Coffee
- Cool Mint
- Menthol
- Peppermint
- Smooth
- Spearmint
- Wintergreen
In January 2025, the FDA authorized the sale of these 20 Zyn products through the standard premarket tobacco product application process (PMTA) after a scientific review.
The manufacturer is now asking for permission to market these products with the claim that “Using Zyn instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.” Tobacco company Philip Morris International (PMI) bought Zyn maker Swedish Match North America in 2022.
An MRTP application must demonstrate the product will or is expected to benefit the health of the population, according to the FDA.
The TPSAC meeting’s discussion will focus on evidence related to the relative health risks of the products, consumer understanding and perceptions of the applicant’s proposed modified risk claim and the potential public health impact of a modified risk marketing order, the FDA said.
Public comments may be submitted through Jan. 21 to docket FDA-2025-N-0835 and comments received on or before Jan. 7 will be provided to the committee, the agency said.
Members help make our journalism possible. Become a CSP member today and unlock exclusive benefits, including unlimited access to all of our content. Sign up here.